Sinigaglia F, Guttinger M, Romagnoli P, Takacs B
Central Research Unit, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Immunol Lett. 1990 Aug;25(1-3):265-70. doi: 10.1016/0165-2478(90)90125-a.
In the case of the malaria CS protein we have shown that there is at least one T cell determinant which is able to bind to and be recognized by most human MHC class II molecules, while for the 190L polypeptide, derived from a conserved region of the p190 merozoite surface protein, we have identified several epitopes recognized by T cell clones in association with different HLA-class II isotypes and alleles. In addition, binding analysis of these epitopes indicated that most of the peptides are able to bind to multiple allelic forms of class II molecules. Although there are important obstacles to malaria vaccine development we believe that, in the light of these results, unresponsiveness in humans, caused by MHC restriction, might not be a major constraint in development of a subunit vaccine.
就疟疾环子孢子蛋白而言，我们已经证明，至少存在一个T细胞决定簇，它能够与大多数人类MHC II类分子结合并被其识别；而对于源自p190裂殖子表面蛋白保守区域的190L多肽，我们已经鉴定出几个表位，这些表位可被T细胞克隆识别，且与不同的HLA - II类同种异型和等位基因相关。此外，对这些表位的结合分析表明，大多数肽能够与II类分子的多种等位基因形式结合。尽管疟疾疫苗开发存在重大障碍，但鉴于这些结果，我们认为，由MHC限制导致的人类无反应性可能不是亚单位疫苗开发中的主要限制因素。
